FDA approves Roche's Enspryng as first at-home subcutaneous treatment for thyroid eye disease

The FDA approved Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment for thyroid eye disease (TED). In the SatraGO-2 trial, proptosis response was 52.9% vs 23.4% for placebo; the SatraGO-1 trial missed its primary endpoint.

Detected & updated continuously · Source: Nebula